Suppr超能文献

用于结直肠癌联合治疗的纳米级药物制剂的进展

Advancements of nanoscale drug formulations for combination treatment of colorectal cancer.

作者信息

Li Liqi, Chen Maohua, Reis Rui L, Kundu Subhas C, Xiao Bo, Shi Xiaoxiao

机构信息

Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.

Department of Pharmacy, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.

出版信息

Int J Pharm. 2025 Apr 15;674:125508. doi: 10.1016/j.ijpharm.2025.125508. Epub 2025 Mar 23.

Abstract

Combination chemotherapy is widely utilized in treating colorectal cancer (CRC), particularly for patients who are ineligible for surgery or those with metastatic CRC (mCRC). While this therapeutic method has demonstrated efficacy in managing CRC and mCRC, its broader clinical application is limited due to the unique physical properties, mechanisms of action, and pharmacokinetics of different chemotherapeutic drugs. Consequently, achieving satisfactory treatment outcomes proves to be challenging. Nanotechnology has given rise to innovative drug systems that are precise, controllable, and highly efficient in drug delivery. These nanoscale drug delivery systems can integrate the advantageous aspects of various therapeutic modalities, including chemotherapy, gene therapy, and immunotherapy. This review aims to explain the application of nano-drug delivery system in the treatment of colorectal cancer. Through its unique physical/chemical properties and biological functions, it can solve the limitations of traditional therapy and achieve more accurate, efficient and safe treatment. The advantages/disadvantages, physical and chemical characteristics of various drug delivery systems are described in detail, and suggestions on selecting reasonable NDDSs according to different drug combination methods are given to achieve the best therapeutic effect. This review paper presents an exhaustive summary of the diverse range of drugs utilized in chemotherapy, in addition to outlining strategies for effectively integrating chemotherapy with other treatment modalities. Furthermore, it delves into the principle of selecting carriers for various drug combinations.

摘要

联合化疗广泛应用于治疗结直肠癌(CRC),特别是对于那些不适合手术的患者或转移性结直肠癌(mCRC)患者。虽然这种治疗方法在管理CRC和mCRC方面已显示出疗效,但其更广泛的临床应用受到不同化疗药物独特的物理性质、作用机制和药代动力学的限制。因此,实现令人满意的治疗结果具有挑战性。纳米技术催生了创新的药物系统,这些系统在药物递送方面精确、可控且高效。这些纳米级药物递送系统可以整合包括化疗、基因治疗和免疫治疗在内的各种治疗方式的优势。本综述旨在解释纳米药物递送系统在结直肠癌治疗中的应用。通过其独特的物理/化学性质和生物学功能,它可以解决传统疗法的局限性,实现更准确、高效和安全的治疗。详细描述了各种药物递送系统的优缺点、物理和化学特性,并根据不同的药物组合方法给出了选择合理的纳米药物递送系统以实现最佳治疗效果的建议。本综述文章除了概述有效将化疗与其他治疗方式整合的策略外,还对化疗中使用的各种药物进行了详尽总结。此外,它还深入探讨了为各种药物组合选择载体的原则。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验